论文部分内容阅读
目的分析人免疫球蛋白联合酚妥拉明治疗小儿重症肺炎的疗效。方法 128例重症肺炎患儿,根据不同治疗方案分为对照组(60例)和研究组(68例)。对照组行常规治疗,研究组行人免疫球蛋白联合酚妥拉明治疗。分析比较两组的肺部啰音、咳嗽、气促的消失时间及血清指标变化情况。结果研究组肺部啰音、咳嗽及气促的消失时间均短于对照组,差异具有统计学意义(P<0.05);两组治疗前血清各指标比较差异均无统计学意义(P>0.05);治疗后研究组IgG水平显著提高且高于对照组,差异具有统计学意义(P<0.05)。结论小儿重症肺炎行酚妥拉明联合人免疫球蛋白治疗效果显著,可有效改善其临床症状及体征,值得临床推广。
Objective To analyze the therapeutic effect of human immunoglobulin combined with phentolamine on severe pneumonia in children. Methods 128 children with severe pneumonia were divided into control group (60 cases) and study group (68 cases) according to different treatment regimens. Control group routine treatment, the study group pedestrian immunoglobulin phentolamine treatment. The pulmonary rales, cough, disappearance of shortness of breath and changes of serum indexes were analyzed and compared between the two groups. Results The disappearance time of pulmonary rales, cough and shortness of breath in the study group were shorter than those in the control group (P <0.05). There was no significant difference in each index between the two groups before treatment (P> 0.05 ). After treatment, the level of IgG in the study group was significantly higher than that in the control group (P <0.05). Conclusions The treatment effect of phentolamine combined with human immunoglobulin in children with severe pneumonia is significant, which can effectively improve its clinical symptoms and signs and is worthy of clinical promotion.